Trump’s Executive Order Sends Psychedelic Drug Stocks on a Trip to New Highs

Psychedelic stocks just had a trip worth paying attention to. A new order is pushing the FDA to fast-track reviews for treatments like ibogaine — a Schedule I compound derived from an African shrub now being studied for PTSD, depression, and addiction. The directive could cut approval timelines from 6–10 months to 1–2 months by granting priority vouchers to “breakthrough therapy” drugs.

• The order backs that push with $50M in federal research funding, and FDA Commissioner Marty Makary said approvals could come as early as this summer.
• Markets reacted fast — Compass PathwaysCMPS
  jumped 42% yesterday, Atai Life SciencesATAI
  rose ~22%, and GH ResearchGHRS
  gained 17%.

Policy high: Jefferies analyst Andrew Tsai called the order an "official stamp of validation to the class," while RBC’s Brian Abrahams described it as "a substantial step towards diminishing regulatory risk." Even so, Schedule I reclassification, clinical data hurdles, and shifting political winds still stand between this push and a dispensary shelf. With Health Secretary Robert F. Kennedy Jr. championing ibogaine and bipartisan support for broader access gaining traction, this trip looks like it’s just getting started.